HYTN Innovations Inc. announced that, through a manufacturing and sales agreement with Promethean BioPharma (Promethean), it has successfully developed, exported and launched cannabis nano-emulsions featuring HYTN's proprietary Elevation Technology® into the Australian medical cannabis market. The products being formulated and manufactured for Promethean (the Products), which are now selling under the Australian Therapeutic Goods Administration (TGA) Special Access and Authorized Prescriber Scheme, showcase HYTN's ability to leverage its partnerships, proprietary manufacturing process and expert formulation skills to deliver novel products into emerging legal cannabis markets. The Products are cannabis oil in water emulsions featuring HYTN's Elevation Technology® and include the following: a high CBD product; a balanced CBD:THC product; a high THC product; and a CBD isolate product.

The Products, which HYTN believes are the first of their kind to reach the Australian market, are packaged in 60mL bottles each containing 1,200 mg of cannabinoids. HYTN, as stated in its business plan, intends to continue to explore opportunities to expand its product capabilities in emerging legal cannabis markets. The Company hopes this will be the first of many projects highlighting its Elevation Technology® for medical purposes.